课题基金 / 基金详情

Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans

Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans
唑尼沙胺治疗酒精依赖退伍军人的有效性
批准号:
8819717
负责人:
ALBERT JOSEPH ARIAS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-10-01 至 2020-09-30

项目摘要

项目成果

ALBERT JOSEPH ARIAS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Title: Effectiveness of Zonisamide in the Treatment of Alcohol-Dependent Veterans ABSTRACT: Veterans have a high prevalence of alcohol dependence (AD), and those with AD also have a high rate of co-occurring psychiatric illnesses. Zonisamide is an extremely promising medicine for treating AD and managing other clinical problems including psychiatric disorders. Zonisamide is an affordable, generic anticonvulsant with unique actions on the major neurotransmitter systems involved in alcoholism, and it has neuroprotective effects. We recently completed a randomized, placebo- controlled pilot study of zonisamide in treating AD that showed significant reductions in heavy drinking, overall drinking, and alcohol craving. Zonisamide was very well tolerated in this study. In this application, we propose a larger (N = 160), 14-week, randomized, double-blind, placebo-controlled, effectiveness study of zonisamide in reducing heavy drinking and improving outcomes in a representative population of heavy-drinking veterans with AD. We describe zonisamide's potential to break through the barriers in the treatment of veterans with AD as well as its unique pharmacology that brings innovation to alcoholism treatment. An inexpensive, hypothesis-driven, exploratory, translational, pharmacogenetic component adds to the innovation and will work towards optimizing outcomes and personalizing treatment for veterans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
  • 批准号:
    10615366
  • 项目类别:
  • 资助金额:
    $159.79万
  • 财政年份:
    2022
  • 负责人:
    ALBERT JOSEPH ARIAS
  • 依托单位:
Olanzapine Augmentation in OUD Patients on Buprenorphine-Naloxone with Comorbid Symptoms of Serious Mental Illness (SMI): A Prospective Observational 8-week Pilot Study
  • 批准号:
    10395719
  • 项目类别:
  • 资助金额:
    $14.73万
  • 财政年份:
    2021
  • 负责人:
    ALBERT JOSEPH ARIAS
  • 依托单位:
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders
  • 批准号:
    10553087
  • 项目类别:
  • 资助金额:
    $64.71万
  • 财政年份:
    2020
  • 负责人:
    ALBERT JOSEPH ARIAS
  • 依托单位:
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders
  • 批准号:
    9894325
  • 项目类别:
  • 资助金额:
    $51.25万
  • 财政年份:
    2020
  • 负责人:
    ALBERT JOSEPH ARIAS
  • 依托单位:
海外基金